Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

פריטים דומים

• The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
  מאת: Hsu, Ping-Chih, et al.
  יצא לאור: (2020)
• The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
  מאת: Ping-Chih Hsu, et al.
  יצא לאור: (2020-02-01)
• The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
  מאת: Hsu, Ping-Chih, et al.
  יצא לאור: (2020)
• The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
  מאת: Liu, Chien-Ying, et al.
  יצא לאור: (2017)
• Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
  מאת: Hsu, Ping-Chih, et al.
  יצא לאור: (2019)